These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 32093531)

  • 1. Modulation of sphingosine-1-phosphate in ulcerative colitis.
    Argollo M; Furfaro F; Gilardi D; Roda G; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):413-420. PubMed ID: 32093531
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
    Peyrin-Biroulet L; Christopher R; Behan D; Lassen C
    Autoimmun Rev; 2017 May; 16(5):495-503. PubMed ID: 28279838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis.
    Vieujean S; Peyrin-Biroulet L
    Expert Opin Drug Metab Toxicol; 2024 Sep; 20(9):881-892. PubMed ID: 39252206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis.
    Rowan C; Ungaro R; Mehandru S; Colombel JF
    Expert Opin Pharmacother; 2022 Jun; 23(8):893-904. PubMed ID: 35503955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.
    Suilik HA; Jaber F; Abuelazm M; Ramadan A; Elzeftawy MA; Elrosasy A; Youssef RA; Abdelazeem B; Hashash JG; Farraye FA; Ghoz H
    Inflamm Res; 2024 Feb; 73(2):183-198. PubMed ID: 38153524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
    Chun J; Giovannoni G; Hunter SF
    Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    McGinley MP; Cohen JA
    Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
    Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
    J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Becker M; Ivanov M; Bhat S
    Ann Pharmacother; 2024 Oct; 58(10):1054-1063. PubMed ID: 38258760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Stewart AP; Bhat S
    Ann Pharmacother; 2022 May; 56(5):592-599. PubMed ID: 34423657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond.
    Neri B; Mancone R; Fiorillo M; Schiavone SC; De Cristofaro E; Migliozzi S; Biancone L
    Expert Opin Pharmacother; 2024 Apr; 25(5):485-499. PubMed ID: 38591242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
    Pérez-Jeldres T; Alvarez-Lobos M; Rivera-Nieves J
    Drugs; 2021 Jun; 81(9):985-1002. PubMed ID: 33983615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis.
    Al-Shamma H; Lehmann-Bruinsma K; Carroll C; Solomon M; Komori HK; Peyrin-Biroulet L; Adams J
    J Pharmacol Exp Ther; 2019 Jun; 369(3):311-317. PubMed ID: 30872391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
    Dumitrescu L; Papathanasiou A; Coclitu C; Garjani A; Evangelou N; Constantinescu CS; Popescu BO; Tanasescu R
    Expert Opin Pharmacother; 2023 Mar; 24(4):495-509. PubMed ID: 36946625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights into sphingosine-1-phosphate receptor activation.
    Yu L; He L; Gan B; Ti R; Xiao Q; Hu H; Zhu L; Wang S; Ren R
    Proc Natl Acad Sci U S A; 2022 Apr; 119(16):e2117716119. PubMed ID: 35412894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etrasimod for the treatment of ulcerative colitis.
    Wils P; Peyrin-Biroulet L
    Immunotherapy; 2023 Apr; 15(5):311-321. PubMed ID: 36789612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ozanimod-exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histological Changes.
    Cohen NA; Weber CR; Cheng JX; Choi D; Garcia NM; Choi NK; Rubin DT
    J Crohns Colitis; 2024 Apr; 18(4):638-641. PubMed ID: 37879626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
    Armuzzi A; Cross RK; Lichtenstein GR; Hou J; Deepak P; Regueiro M; Wolf DC; Akukwe L; Ahmad HA; Jain A; Kozinn M; Wu H; Petersen A; Charles L; Long M
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1067-1076.e3. PubMed ID: 38040274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke.
    Salas-Perdomo A; Miró-Mur F; Gallizioli M; Brait VH; Justicia C; Meissner A; Urra X; Chamorro A; Planas AM
    Sci Rep; 2019 Jun; 9(1):8309. PubMed ID: 31165772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.
    Wang J; Goren I; Yang B; Lin S; Li J; Elias M; Fiocchi C; Rieder F
    Aliment Pharmacol Ther; 2022 Feb; 55(3):277-291. PubMed ID: 34932238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.